ROS1 G2032R is the dominant solvent-front resistance mutation after crizotinib or entrect...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ROS1-G2032R-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ROS1-FUSION |
|---|---|
| Variant | G2032R (acquired resistance) |
| Disease | DIS-NSCLC |
| ESCAT tier | IB |
| Recommended combinations | repotrectinib monotherapy |
| Contraindicated monotherapy | crizotinib (resistant), entrectinib (resistant), ceritinib (resistant) |
| Evidence summary | ROS1 G2032R is the dominant solvent-front resistance mutation after crizotinib or entrectinib. Repotrectinib retains activity against G2032R (TRIDENT-1, Drilon 2024) — ORR ~58% in TKI-pretreated + G2032R subset — and is the standard salvage TKI. Lorlatinib has variable activity vs G2032R. |
Notes
OncoKB R1. ctDNA at progression preferred for resistance detection. Compound G2032R+L2026M may resist all current TKIs — consider chemo or trial enrollment.
Used By
No reverse references found in the YAML corpus.